Premium
Wirksamkeit von Flutrimazol‐1%‐Puder in der Behandlung der Tinea pedis
Author(s) -
Pereda J.,
Noguera X.,
Boncompte E.,
Algueró M.,
Izquierdo I.
Publication year - 2003
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.2003.00849.x
Subject(s) - bifonazole , tolerability , medicine , adverse effect , randomized controlled trial , itching , dermatology , cure rate , clinical trial , clinical efficacy , therapeutic effect , antifungal
Summary The aim of the study was to compare the efficacy and tolerability of flutrimazole 1% powder vs. bifonazole 1% powder in treating tinea pedis. A multicentre, double blind, randomized, parallel and comparative study was conducted. Two hundred and twenty‐two patients with clinically and mycologically confirmed tinea pedis were randomized to flutrimazole ( n = 136) or bifonazole ( n = 138) 1% powder applied twice daily for 4 weeks. The corresponding clinical cure rates were assessed at 2 and 4 weeks of treatment, and the global (clinical and mycological) cure rates were determined at the fourth week. Clinical cure rates were 83.5 and 82.4% for flutrimazole and bifonazole, respectively (95% CI: −0.0806 to 0.1009). Global cure rates were observed in 65.3 and 70.1% of patients treated with flutrimazole and bifonazole, respectively (95% CI: −0.0828 to 0.1779). Three non serious adverse events at the application site ‐ itching (one patient per group) and dishydrotic eczema (one patient treated with flutrimazole) – were recorded during the study. These results support that flutrimazol 1% powder applied twice daily for a duration of 4 weeks is highly effective in the treatment of tinea pedis, showing a similar therapeutic profile with that of bifonazole 1% powder.